Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant
Peter J
PJ
The LIGHT Laboratories, University of Leeds, Clarendon Way, Leeds, UK. p.j.grant@leeds.ac.uk
D003257:Consumer Product Safety; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced*; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone